ResearchHub Logo
Currency
Display format
RSCUSD

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

Authors
Thomas CluzeauMarie SébertPierre Fenaux
Journal
Journal of Clinical Oncology
Published
February 18, 2021
Sign in to comment
Add a comment...

No comments yet. Start the conversation!

Your contribution could help open science.

Supporters

Support the authors with ResearchCoin

Topics

DOI

10.1200/jco.20.02342

License

cc-by-nc-nd

Other Formats

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodyspla... | ResearchHub